EyePoint Pharmaceuticals (vorher: PSIVIDA) startet durch !! (Seite 1140)
eröffnet am 29.01.04 09:28:54 von
neuester Beitrag 23.12.23 12:39:57 von
neuester Beitrag 23.12.23 12:39:57 von
Beiträge: 12.859
ID: 814.884
ID: 814.884
Aufrufe heute: 0
Gesamt: 1.588.476
Gesamt: 1.588.476
Aktive User: 0
ISIN: AU000000PVA7 · WKN: A0Q4DA
1,8250
EUR
-2,93 %
-0,0550 EUR
Letzter Kurs 03.05.18 Tradegate
Werte aus der Branche Pharmaindustrie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,8300 | +161,43 | |
| 3,0920 | +22,21 | |
| 9,2900 | +20,96 | |
| 111,75 | +18,87 | |
| 0,6400 | +18,52 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 15,550 | -17,02 | |
| 9,7200 | -19,60 | |
| 0,9250 | -23,55 | |
| 14,510 | -32,32 | |
| 8,0000 | -36,76 |
Beitrag zu dieser Diskussion schreiben
Feedback
Morgen!!
Global nanotechnology company pSivida Ltd is pleased to announce that in connection with the NASDAQ listing, pSivida will be hosting an investor meeting on Thursday 27th January.
pSivida`s Managing Director Mr. Gavin Rezos will discuss pSivida’s use of BioSilicon™ to develop innovative methods of controllable drug delivery and diagnostics, the company’s clinical trial timeline, product pipeline and partnerships, and commercial outlook for the future.
Those who wish to access the webcast may log onto http://www.psivida.com/News/Presentations.asp." target="_blank" rel="nofollow ugc noopener">http://www.psivida.com/News/Presentations.asp.
The webcast will be available beginning at 1:00 p.m. US Eastern Time.
Kind Regards
http://www.psivida.com/News/Presentation.asp.
Josh Mann
Investor Relations
pSivida Limited
w: http://www.psivida.com
e: joshuamann@psivida.com
t: +61 8 9226 5099
f: +61 8 9226 5499
Gruss R.
Global nanotechnology company pSivida Ltd is pleased to announce that in connection with the NASDAQ listing, pSivida will be hosting an investor meeting on Thursday 27th January.
pSivida`s Managing Director Mr. Gavin Rezos will discuss pSivida’s use of BioSilicon™ to develop innovative methods of controllable drug delivery and diagnostics, the company’s clinical trial timeline, product pipeline and partnerships, and commercial outlook for the future.
Those who wish to access the webcast may log onto http://www.psivida.com/News/Presentations.asp." target="_blank" rel="nofollow ugc noopener">http://www.psivida.com/News/Presentations.asp.
The webcast will be available beginning at 1:00 p.m. US Eastern Time.
Kind Regards
http://www.psivida.com/News/Presentation.asp.
Josh Mann
Investor Relations
pSivida Limited
w: http://www.psivida.com
e: joshuamann@psivida.com
t: +61 8 9226 5099
f: +61 8 9226 5499
Gruss R.
Mmmh...
8000 kann auch nicht stimmen, wärn bisschen wenig
8000 kann auch nicht stimmen, wärn bisschen wenig
Bin gespannt was morgen abgeht, die aussies wissen es wohl auch nicht so recht.
Hallo,
soweit ich es mitgekriegt, kommen die Aktien gezehntelt auf den Amimarkt.
Wären bei 80000 doch nur 8000!
Gruß
Coltrane
soweit ich es mitgekriegt, kommen die Aktien gezehntelt auf den Amimarkt.
Wären bei 80000 doch nur 8000!
Gruß
Coltrane
in Time&Sale stehen auf BSI 80000 im Bid.Na jetzt werden aber richtig welche aufmerksam auf Psivida.Morgen wird ein schöner Tag
gruß an toothstone
gruß an toothstone
Trading Spotlight
Danke @ radegast,
dann warten ma mal bis do.
Macht es nicht sinn die Veranstaltungen für potenzielle Investoren nicht erst nach dem Börsengang in Usa zu machen?
dann warten ma mal bis do.
Macht es nicht sinn die Veranstaltungen für potenzielle Investoren nicht erst nach dem Börsengang in Usa zu machen?
Guten Morgen!!
ASX/MEDIA RELEASE 25th January 2005
ADSs Slated to Commence Trading Citigroup selected as Depositary Bank for National Market Level II ADR
Global nanotechnology company pSivida Limited (ASX: PSD), is pleased to
announce that its U.S. securities registration has been declared effective and it has
received preliminary approval from NASDAQ for the listing of its American Depositary
Shares (ADSs) represented by American Depositary Receipts (ADRs) on the
NASDAQ National Market. The Company has also selected Citigroup as it
Depositary Bank to administer the ADR programme.
pSivida expects its ADSs to commence trading on NASDAQ’s National Market on
Thursday 27th January 2005 under the ticker symbol PSDV. The ADSs will trade on a
10:1 ratio to the Company’s ordinary shares (i.e., 10 pSivida shares for every 1
ADR). pSivida’s ordinary shares will continue to trade on the Australian and
Frankfurt Stock Exchanges.
pSivida Managing Director, Mr. Gavin Rezos said, “The NASDAQ listing will be an
important step forward for pSivida as it looks to achieve success in the world’s
largest market in terms of capital and pharmaceutical products. We are actively
looking to expand our investor base in the U.S. and are very pleased to appoint
Citigroup as our Depositary Bank.”
Citigroup Depositary Receipt Services is a market leader in bringing quality issuers to
the U.S. and international markets and promoting Depositary Receipts as an effective
capital markets tool. The appointment of Citigroup Depositary Receipt Services
provides pSivida with a gateway to the resources of Citigroup and the means to
diversify its shareholder bases and increase liquidity.
Importantly the listing will offer access to U.S. investors that are currently prohibited
or limited in owning foreign securities or who only invest in companies that publish
results computed in accordance with US GAAP.
pSivida is a global nanotechnology company committed to the biomedical sector and
the development of products in healthcare. The company’s focus is the development
and commercialisation of a modified form of silicon (porosified or nano-structured
silicon) known as BioSilicon™. As a new and exciting biocompatible and
biodegradable material, BioSilicon offers multiple potential applications across the
high growth healthcare sector, including controlled release drug delivery, targeted
cancer therapies (including brachytherapy and localized chemotherapy), tissue
engineering and orthopedics. Potential diagnostics applications are being developed
through its subsidiary AION Diagnostics Limited.
pSivida plans to hold a series of informational meetings in the U.S. during February
and March for investors and potential investors.
For more information about Citigroup and ADRs please see Notes to Editors.
-ENDS
Gruss R.
ASX/MEDIA RELEASE 25th January 2005
ADSs Slated to Commence Trading Citigroup selected as Depositary Bank for National Market Level II ADR
Global nanotechnology company pSivida Limited (ASX: PSD), is pleased to
announce that its U.S. securities registration has been declared effective and it has
received preliminary approval from NASDAQ for the listing of its American Depositary
Shares (ADSs) represented by American Depositary Receipts (ADRs) on the
NASDAQ National Market. The Company has also selected Citigroup as it
Depositary Bank to administer the ADR programme.
pSivida expects its ADSs to commence trading on NASDAQ’s National Market on
Thursday 27th January 2005 under the ticker symbol PSDV. The ADSs will trade on a
10:1 ratio to the Company’s ordinary shares (i.e., 10 pSivida shares for every 1
ADR). pSivida’s ordinary shares will continue to trade on the Australian and
Frankfurt Stock Exchanges.
pSivida Managing Director, Mr. Gavin Rezos said, “The NASDAQ listing will be an
important step forward for pSivida as it looks to achieve success in the world’s
largest market in terms of capital and pharmaceutical products. We are actively
looking to expand our investor base in the U.S. and are very pleased to appoint
Citigroup as our Depositary Bank.”
Citigroup Depositary Receipt Services is a market leader in bringing quality issuers to
the U.S. and international markets and promoting Depositary Receipts as an effective
capital markets tool. The appointment of Citigroup Depositary Receipt Services
provides pSivida with a gateway to the resources of Citigroup and the means to
diversify its shareholder bases and increase liquidity.
Importantly the listing will offer access to U.S. investors that are currently prohibited
or limited in owning foreign securities or who only invest in companies that publish
results computed in accordance with US GAAP.
pSivida is a global nanotechnology company committed to the biomedical sector and
the development of products in healthcare. The company’s focus is the development
and commercialisation of a modified form of silicon (porosified or nano-structured
silicon) known as BioSilicon™. As a new and exciting biocompatible and
biodegradable material, BioSilicon offers multiple potential applications across the
high growth healthcare sector, including controlled release drug delivery, targeted
cancer therapies (including brachytherapy and localized chemotherapy), tissue
engineering and orthopedics. Potential diagnostics applications are being developed
through its subsidiary AION Diagnostics Limited.
pSivida plans to hold a series of informational meetings in the U.S. during February
and March for investors and potential investors.
For more information about Citigroup and ADRs please see Notes to Editors.
-ENDS
Gruss R.
vor allem an solchen TAgen wie heute
In der Ruhe liegt die Kraft, die NASDAQ wird es richten
Psivida, Nun komm doch endlich etwas hoch oder Explooooodierst du bald? 
Und gib uns ein Paar NEW`s
Durchsuchen
